Sanara MedTech Q2 revenue up 28%
Overview
Sanara MedTech Q2 revenue rises 28% yr/yr, beating analyst expectations
Company reports Q2 net loss of $2 mln, narrowing from previous year
Sanara to evaluate strategic alternatives for Tissue Health Plus subsidiary
Outlook
Sanara projects cash investment in THP strategy between $5.5 mln and $6.5 mln
Company evaluating strategic alternatives for Tissue Health Plus subsidiary
Sanara aims to capitalize on growth opportunities in Sanara Surgical segment
Result Drivers
SOFT TISSUE REPAIR - Revenue growth driven by increased demand for CellerateRX Surgical and BIASURGE products
SANARA SURGICAL EXPANSION - Growth attributed to expanding distributor network and penetration into new healthcare facilities
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $25.80 mln | $25.10 mln (2 Analysts) |
Q2 EPS |
| -$0.23 |
|
Q2 Net Income |
| -$2 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Sanara Medtech Inc is $49.00, about 43.9% above its August 12 closing price of $27.47
Press Release: ID:nGNX3mTwh4
Related Articles
U.S. Stock Market Risk Assessment: Learning from History, Mid-Term Outlook Remains Secure
We argue that the Federal Reserve’s monetary policy is the most critical factor influencing the stock market.
Don't Miss Walmart's Aug 21 Earnings: $0.73 EPS Forecast, Grocery + E-Com Dual Engines – Unlimited Upside Potential?
TradingKey - Walmart's stock price has shown an overall fluctuating upward trend since the release of its first-quarter earnings report, benefiting from investors' favoritism towards Walmart as a defensive stock, as well as expectations for its stable growth in e-commerce and grocery businesses.
Powell's Jackson Hole Speech: For U.S. Stocks, Hawk or Dove Signal Could Be a Lose-Lose?
TradingKey - As U.S. inflation and labor market data show signs of rebalancing, Treasury traders and Wall Street banks have largely priced in a rate cut at the September FOMC meeting — the first of 2025. Yet both a more dovish-than-expected tone and a potential surprise hawkish signal from Fed Chair
Eurozone Q2 GDP Commentary: Will the Euro's Upward Momentum Persist?
TradingKey - On 14 August 2025, Eurostat published Q2 GDP figures, revealing a drop in the Eurozone's quarter-on-quarter growth from 0.6% in the first quarter to 0.1%. Consequently, annual growth eased from 1.5% to 1.4%. The slowdown primarily stems from the diminishing boost from European...
Bridgewater Associates Q2 2025 13F Analysis: Founder Ray Dalio’s Final Act
TradingKey - Bridgewater Associates, the world’s largest hedge fund and renowned for its macroeconomic analysis, continues to command market respect with its “risk parity” strategy and precise economic cycle timing.
